Pharma companies are expanding their presence in mental health tech. From digital therapeutics to drug development, we take a look at how Pfizer, Johnson & Johnson, and Sanofi are exploring opportunities in this space.
Access to mental healthcare is more important than ever.
During the first year of the Covid-19 pandemic, global anxiety and depression rates increased by 25%. Meanwhile, 42% of Americans who reported needing mental healthcare over the past 12 months did not get it because of low availability and affordability.
Leading pharmaceutical companies are working to break down these barriers and make mental healthcare more accessible. Companies like Pfizer, Johnson & Johnson, and Sanofi are developing new tech solutions and novel drugs to improve emotional, psychological, and social wellbeing.